SE9900473D0 - Inhibitor of endothelial cell proliferation - Google Patents

Inhibitor of endothelial cell proliferation

Info

Publication number
SE9900473D0
SE9900473D0 SE9900473A SE9900473A SE9900473D0 SE 9900473 D0 SE9900473 D0 SE 9900473D0 SE 9900473 A SE9900473 A SE 9900473A SE 9900473 A SE9900473 A SE 9900473A SE 9900473 D0 SE9900473 D0 SE 9900473D0
Authority
SE
Sweden
Prior art keywords
angiogenesis
egcg
inhibitor
cell proliferation
endothelial cell
Prior art date
Application number
SE9900473A
Other languages
Swedish (sv)
Inventor
Cao Yihai
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE9900473A priority Critical patent/SE9900473D0/en
Publication of SE9900473D0 publication Critical patent/SE9900473D0/en
Priority to AU25673/00A priority patent/AU2567300A/en
Priority to PCT/IB2000/000193 priority patent/WO2000047193A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Epigallocatechin-3-gallate (EGCG) inhibits angiogenesis and is useful in treatment and prevention of angiogenesis-dependent and -related diseases, including rheumatoid arthritis, psoriasis, ocular angiogenic diseases, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal angiogenesis, graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularisation, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, cat scratch disease (Rochele minalia quintosa) and ulcers (Helicobacter pyloriinfection). EGCG may be provided by means of green tea.
SE9900473A 1999-02-12 1999-02-12 Inhibitor of endothelial cell proliferation SE9900473D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9900473A SE9900473D0 (en) 1999-02-12 1999-02-12 Inhibitor of endothelial cell proliferation
AU25673/00A AU2567300A (en) 1999-02-12 2000-02-14 Inhibition of angiogenesis with epigallocatechin-3-gallate
PCT/IB2000/000193 WO2000047193A2 (en) 1999-02-12 2000-02-14 Inhibition of angiogenesis with epigallocatechin-3-gallate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900473A SE9900473D0 (en) 1999-02-12 1999-02-12 Inhibitor of endothelial cell proliferation

Publications (1)

Publication Number Publication Date
SE9900473D0 true SE9900473D0 (en) 1999-02-12

Family

ID=20414446

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900473A SE9900473D0 (en) 1999-02-12 1999-02-12 Inhibitor of endothelial cell proliferation

Country Status (3)

Country Link
AU (1) AU2567300A (en)
SE (1) SE9900473D0 (en)
WO (1) WO2000047193A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5089400A (en) * 1999-06-07 2000-12-28 University Of Sheffield, The Arthritis treatment
US6248341B1 (en) * 2000-01-14 2001-06-19 Color Access, Inc. Method of treating topical angiogenesis-related disorders
WO2002064178A1 (en) * 2001-02-15 2002-08-22 William Ransom & Son Plc Use of green tea extract for wound healing
GB0103742D0 (en) * 2001-02-15 2001-04-04 William Ransom & Son Plc Wound healing
AU2002357399A1 (en) * 2001-12-28 2003-07-24 Research Development Foundation Polyphenol inhibition of nuceloside diphosphate kinase-B activity and cancer metastasis
FR2842102B1 (en) * 2002-07-10 2005-10-28 Cep USE OF A TEA EXTRACT TO CONTROL THE RELEASE OF IL8, PRO-INFLAMMATORY CYTOKINE AND ITS INCORPORATION INTO COSMETIC AND / OR DERMATOLOGICAL PREPARATIONS
PT102931B (en) * 2003-03-28 2005-08-31 Univ Do Porto USE OF BLOCKERS OF THE LONG TERM INHIBITION OF THE ACTIVITIES OF ATPASE NA + K + E / OR OF THE NA + / H + EXCHANGE, IN THE PREPARATION OF A MEDICATION INTENDED FOR THE THERAPYTESTINAL
WO2005000330A1 (en) 2003-05-28 2005-01-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Angiogenic agents from plant extracts, gallic acid, and derivatives
KR100601080B1 (en) 2004-08-26 2006-07-19 가톨릭대학교 산학협력단 Rheumatoid arthritis treating agent having --epigallocatechin gallate as active ingredient
US20070249545A1 (en) * 2004-08-27 2007-10-25 Rodriguez-Lopez Jose N Dihydrofolate reductase inhibition by epigallocatechin gallate compounds
EP1704862A1 (en) * 2005-03-24 2006-09-27 Rottapharm S.p.A. 2,5-bis(tetrahydroxybutyl)pyrazines for the treatment of osteoarthritis and rheumatoid arthritis
DE102005029845B4 (en) * 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Method for the diagnosis of rheumatic diseases
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US20090226547A1 (en) * 2008-03-05 2009-09-10 Gilbard Jeffrey P Dietary Supplement For Eye Health
TW201412325A (en) * 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
CN108272794A (en) * 2018-01-17 2018-07-13 苏州大学 The application of Epigallo-catechin gallate (EGCG)
CN114948935B (en) * 2022-03-28 2024-05-17 厦门大学 Gallic acid derivative nano-drug, preparation method and application
WO2024170772A1 (en) * 2023-02-17 2024-08-22 Mim Neurosciences Ab Epigallocatechin-3-gallate (egcg) analogs for use in the treatment of diseases in which an increase of nad+ is beneficial such as glaucoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238728A (en) * 1985-04-16 1986-10-24 Mitsui Norin Kk Complex substance of extract of tea leaf and active aluminum hydroxide
JP2903318B2 (en) * 1989-04-04 1999-06-07 日研フード株式会社 Antioxidant stress substance
JP3002919B2 (en) * 1991-11-25 2000-01-24 太陽化学株式会社 Composition for preventing gastritis, stomach or duodenal ulcer
JPH08217674A (en) * 1995-02-16 1996-08-27 Noda Sangyo Kagaku Kenkyusho Inhibitor of histidine decarboxylase
IT1275905B1 (en) * 1995-03-14 1997-10-24 Indena Spa POLYPHENOLIC FRACTIONS OF TEA, THEIR USE AND FORMULATIONS THAT CONTAIN THEM
CA2175985A1 (en) * 1995-05-10 1996-11-11 Yoichi Kiyosuke Pharmaceutical composition containing substance inhibiting hsp47 production
JPH09227374A (en) * 1996-02-28 1997-09-02 Taiyo Kagaku Co Ltd Composition for inhibiting production of stress protein
DE19627344A1 (en) * 1996-07-01 1998-01-08 Vitasyn Gmbh Entwicklung & Ver Therapeutic composition containing epicatechin and/or theaflavin
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
JP4507027B2 (en) * 1998-12-04 2010-07-21 明治乳業株式会社 MMP inhibitor

Also Published As

Publication number Publication date
WO2000047193A3 (en) 2001-12-06
AU2567300A (en) 2000-08-29
WO2000047193A2 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
SE9900473D0 (en) Inhibitor of endothelial cell proliferation
Wilkinson-Berka et al. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy
Holme et al. Incidence of lesions of the saphenous nerve after partial or complete stripping of the long saphenous vein.
Rubanyi The role of endothelium in cardiovascular homeostasis and diseases
Badimon Atherosclerosis and thrombosis: lessons from animal models
Mulder et al. Cellular senescence and matrix metalloproteinase activity in chronic wounds: relevance to debridement and new technologies
Lohsiriwat et al. Comparison of the ionic silver-containing Hydrofiber* and paraffin gauze dressing on split-thickness skin graft donor sites
Herouy et al. Matrix metalloproteinases and venous leg ulceration
Gustafsson et al. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time
Maitre et al. Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine
Hess Arterial ulcer checklist
Riedel et al. Immunohistochemical analysis of radiation-induced non-healing dermal wounds of the head and neck
Emmons et al. Palliative wound care, part 2: application of principles
RU2003124748A (en) PHARMACEUTICAL COMPOSITIONS THAT SUPPRESS VASCULAR PROLIFERATION AND METHOD OF APPLICATION
Adams et al. Role of neutrophil membrane proteases in fibrin degradation
Laher et al. Lisinopril in elderly patients with hypertension
Zimmerman et al. Surgical implications of therapeutic angiogenesis
TR200200211T2 (en) Treatment and drug screening methods.
Mirshahi et al. Expression of elastase and fibrin in venous leg ulcer biopsies: a pilot study of pentoxifylline versus placebo
Ray et al. Epsilon-aminocaproic acid promotes the release of α2-antiplasmin during and after cardiopulmonary bypass
Fleck et al. Newer debridement methods for wound bed preparation
Morishima et al. In Vitro Characteristics, Anticoagulant Effects and In Vivo Antithrombotic Efficacy of a Novel, Potent and Orally Active Direct Factor Xa Inhibitor, DU-176b.
Cole et al. Adjuvant use of acoustic pressure wound therapy for treatment of chronic wounds: a retrospective analysis
Lesher Jr et al. Subclinical hypothyroidism during potassium iodide therapy for lymphocutaneous sporotrichosis.
Hulthén Nephrin: a pivotal molecule in proteinuria influenced by angiotensin II